Business Context and Reporting Period
This Form 8-K filing by Molina Healthcare, Inc. reports a significant executive leadership change. The report date is October 10, 2017, covering events occurring on October 9, 2017. The filing details the appointment of a new President and Chief Executive Officer (CEO) and the concurrent resignation of the interim CEO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Appointment of CEO: Joseph M. Zubretsky was appointed President, CEO, and Director, effective November 6, 2017. He joins from The Hanover Insurance Group, Inc., where he served as President and CEO.
- Resignation of Interim CEO: Joseph W. White resigned as Interim President and CEO effective upon Mr. Zubretsky's start date. Mr. White will continue to serve as Chief Financial Officer and Treasurer.
Compensation, Outlook, and Risks
Compensation Arrangements
The filing outlines a comprehensive employment agreement for Mr. Zubretsky:
- Base Salary: $1,300,000 annually.
- Signing Bonus: $4,000,000 cash, subject to repayment if employment terminates for "Cause" or without "Good Reason" within two years.
- Annual Bonus: Target of 150% of base salary (starting 2018), with a maximum of 300%. No bonus eligibility for 2017.
- Equity Grants:
- Option to purchase 375,000 shares granted October 9, 2017, vesting over three years.
- Restricted Stock Units (RSUs) valued at $6,000,000 (performance-based) and Restricted Stock valued at $4,000,000 (time-based, vesting over four years) to be granted in Q1 2018.
- Severance:
- Termination without Cause/Good Reason: 150% of base salary and target bonus, plus acceleration of time-based equity awards.
- Termination within 24 months of Change in Control: 200% of base salary and target bonus, plus acceleration of time-based and target-level performance-based equity awards.
Risks and Contingencies
The agreement includes standard covenants regarding confidentiality, non-solicitation, non-competition, and non-disparagement, expiring 18 months post-employment. All payments are subject to the Company's Clawback Policy.
Investor Verification Checklist
- Verify the exact start date of November 6, 2017, for the transition of CEO duties.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the vesting schedule and performance metrics for the $6,000,000 RSU grant to be issued in Q1 2018.
- Monitor the press release (Exhibit 99.1) for additional strategic commentary from the new CEO.